We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

The Value of Biomarker Comparisons Between Autosomal Dominant and Late-Onset Alzheimer Disease

Adam S. Fleisher, MD, MAS1,2
[+] Author Affiliations
1Eli Lilly and Company, Indianapolis, Indiana
2Department of Neuroscience, University of California, San Diego
JAMA Neurol. 2014;71(9):1087-1088. doi:10.1001/jamaneurol.2014.1747.
Text Size: A A A
Published online


Autosomal dominant Alzheimer disease (ADAD) accounts for less than 1% of those affected by Alzheimer disease (AD) in the world’s population. However, because temporal progression is fairly predictable and the underlying neuropathology and clinical presentation parallel that of late-onset sporadic AD (sAD), it provides an important human model for research on more prevalent sAD. More than 500 families with more than 200 known mutations in the amyloid precursor protein and presenilin genes associated with amyloid-β (Aβ) production have been identified. Much of what we know about the molecular and neuropathologic origins of AD stems from discoveries in these genetic variants and associated animal models. Genetic Aβ overproduction disorders offer researchers the opportunity to evaluate the natural progression of AD in a highly predictable model. Application of fluid biomarkers and neuroimaging tools in the study of ADAD can aid in the understanding of early neuropathological changes and assist in identifying predictive presymptomatic markers of clinically significant AD. On the other hand, although ADAD has many similarities in clinical progression and pathology to sAD, these are arguably diseases with distinct inciting mechanisms that lead to similar downstream effects.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

1 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections

Care at the Close of Life: Evidence and Experience
Alzheimer Disease: "It's OK, Mama, If You Want to Go, It's OK"

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Supplemental Content